Table of Contents
I
194
Stephanie van Hoppe
Preface
7
Chapter 1 Introduction
9
Chapter 2 Breast cancer resistance protein (BCRP/ABCG2) and P-glycoprotein (P-gp/ABCB1) transport afatinib and restrict its oral availability and brain accumulation
21
Chapter 3 Brain accumulation of osimertinib and its active metabolite AZ5104 is restricted by ABCB1 (P-glycoprotein) and ABCG2 (Breast Cancer Resistance Protein)
43
Chapter 4 P-glycoprotein (MDR1/ABCB1) restricts brain penetration of the Bruton’s tyrosine kinase inhibitor ibrutinib while Cytochrome P450-3A (CYP3A) limits its oral bioavailability
69
Chapter 5 Brain accumulation of ponatinib and its active metabolite N-desmethyl ponatinib is limited by P-glycoprotein (PGP/ABCB1) and breast cancer resistance protein (BCRP/ABCG2)
99
Chapter 6 The impact of Organic Anion-Transporting Polypeptides (OATPs) on disposition and toxicity of antitumor drugs; insights from knockout and humanized mice
125
Chapter 7 Conclusions and future perspectives
167
Chapter 8 Summary
173
Nederlandse samenvatting
181
Résumé en français
183
Curriculum vitae
185
List of publications
186
Acknowledgements
188
Made with FlippingBook
RkJQdWJsaXNoZXIy MTk4NDMw